Free tool
FAERS Monitor: Tascenso Odt
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214962 or its brand name (Tascenso Odt, Fingolimod Lauryl Sulfate). Reports on generic versions are filed under their own applications.
Reports
218
Serious
64
29% of reports
Hospitalization
21
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- heart rate decreased28
- fatigue25
- headache21
- dizziness15
- somnolence12
- multiple sclerosis relapse11
- gait disturbance8
- nausea8
- asthenia7
- drug ineffective7
- hypertension7
- hospitalisation6
- off label use6
- abdominal pain upper5
- fall5
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 73 |
| 2024 | 88 |
| 2025 | 44 |
| 2026 | 13 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,941 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| heart rate decreasedSignal | 28 | 77.0 | 54.5 | 2,026 |
| multiple sclerosis relapseSignal | 11 | 15.5 | 8.7 | 135 |
| somnolenceSignal | 12 | 5.8 | 3.3 | 43 |
| gait disturbanceSignal | 8 | 4.0 | 2.0 | 15 |
| hospitalisationSignal | 6 | 3.8 | 1.7 | 10 |
| headacheSignal | 21 | 3.2 | 2.2 | 31 |
| hypertensionSignal | 7 | 3.2 | 1.5 | 9 |
| fatigueSignal | 25 | 3.1 | 2.1 | 35 |
| dizzinessSignal | 15 | 2.9 | 1.8 | 17 |
| abdominal pain upper | 5 | 2.3 | 1.0 | 3 |
| asthenia | 7 | 1.8 | 0.9 | 2 |
| fall | 5 | 1.4 | 0.6 | 0 |
| nausea | 8 | 1.0 | 0.5 | 0 |
| off label use | 6 | 0.7 | 0.3 | 1 |
| drug ineffective | 7 | 0.5 | 0.2 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.